Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Urothelial Bladder Carcinoma × pembrolizumab × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Carcinoma, Non-Small-Cell Lung 115 Melanoma 81 Squamous Cell Carcinoma of Head and Neck 76 Breast Neoplasms 63 Triple Negative Breast Neoplasms 54 Parkinson Disease 4, Autosomal Dominant Lewy Body 39 Head and Neck Neoplasms 39 Ovarian Neoplasms 36 Stomach Neoplasms 34 Lung Neoplasms 34 Colorectal Neoplasms 34 Neoplasm Metastasis 32 Neoplasms 30 Carcinoma, Renal Cell 29 Pancreatic Neoplasms 26 Urinary Bladder Neoplasms 24 Carcinoma, Hepatocellular 24 Carcinoma, Transitional Cell 23 Recurrence 19 Uterine Cervical Neoplasms 18 Hodgkin Disease 18 Prostatic Neoplasms 17 Glioblastoma 17 Esophageal Neoplasms 17 Endometrial Neoplasms 17 Fallopian Tube Neoplasms 15 Brain Neoplasms 15 Sarcoma 14 Carcinoma, Squamous Cell 14 Adenocarcinoma 14

Interventions

zimberelimab 1 sacituzumab govitecan 1 pembrolizumab 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02736266 2023-07-18

PURE-01

Fondazione IRCCS Istituto Nazionale dei Tumori, Milano

Phase 2 Completed

Urothelial Bladder Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡